Search clinical trials for: Durvalumab

Total 752 results

Celgene

Terminated

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

Multiple Myeloma

United States, Canada, Spain, Italy, Denmark, United Kingdom, Belgium, Sweden, Germany
MedImmune LLC

Completed

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom
Institut Claudius Regaud
AstraZeneca

Completed

Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. (CITHARE)

Oropharyngeal Squamous Cell Carcinoma

France
Centre Georges Francois Leclerc
AstraZeneca

Completed

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (MEDITREME)

Colorectal Cancer Metastatic

France
Simon C Pacey, MD
AstraZeneca

Active, not recruiting

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab (CALIBRATION)

Oesophageal Cancer

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris

Withdrawn

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors (MATILDA)

Metastatic Colorectal Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Prostate Adenocarcinoma | Stomach Adenocarcinoma
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Targovax ASA

Completed

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Colorectal Cancer | Ovarian Cancer | Appendiceal Cancer

United States
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands
Asan Medical Center

Active, not recruiting

Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Korea, Republic of
AstraZeneca

Active, not recruiting

Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)

Small-Cell Lung Cancer

Poland, Korea, Republic of, United States, Spain
AstraZeneca

Approved for marketing

Himalaya Early Access Program

Unresectable Hepatocellular Carcinoma

United States
Mayo Clinic

Completed

Fluid Volume During Fluid Shifts

Development of Non-invasive Protocol

United States
Radboud University Medical Center
AstraZeneca

Completed

Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer (Donan)

Non-small Cell Lung Cancer

Netherlands
NSABP Foundation Inc

Completed

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Colorectal Cancer Metastatic

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Melanoma | Sarcoma | Breast Cancer | Solid Tumor | Prostate Cancer | Bladder Cancer | Head and Neck Squamous Cell Carcinoma | Cutaneous T-Cell Lymphoma | Renal Cancer | Merkel Cell Carcinoma | Testicular Cancer

United States
Centre hospitalier de l'Université de Montréal...
AstraZeneca

Active, not recruiting

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma

Canada
Yale University

Completed

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Breast Neoplasms

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Cure Brain Cancer Foundation...

Completed

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Glioblastoma

United States, Australia
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Multiple Myeloma Research...

Terminated

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Multiple Myeloma

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer

United States
Ludwig Institute for Cancer Research
Xcovery Holding Company, LLC; Cancer Research Institute, New York City; MedImmune...

Completed

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Carcinoma | NSCLC | Non-small Cell Lung Cancer

United States
Ludwig Institute for Cancer Research
Celgene; Cancer Research Institute, New York City; MedImmune LLC

Completed

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Ovarian Cancer

United States, Switzerland
Ludwig Institute for Cancer Research
Boehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...

Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NSCLC | Metastatic Non-small Cell Lung Cancer

United States
Baylor College of Medicine

Completed

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
AIO-Studien-gGmbH
AstraZeneca

Withdrawn

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

NSCLC Stage IV

Germany
Yale University
VA Connecticut Healthcare System

Completed

Fish Oil vs. Placebo on Subjective Effects of Alcohol

Alcohol Dependence

United States
Dana-Farber Cancer Institute
AstraZeneca

Completed

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Muscle Invasive Bladder Cancer

United States
Duke University
AstraZeneca

Completed

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)

Triple Negative Breast Cancer

United States
Spanish Oncology Genito-Urinary Group
AstraZeneca; MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach (IMMUNOPRESERVE)

Invasive Bladder Cancer

Spain
MedImmune LLC

Completed

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Head and Neck Cancer | Human Papilloma Virus

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
ARCAGY/ GINECO GROUP

Active, not recruiting

Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse (BOLD)

Epithelial Ovarian Cancer | Relapse

France
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
Memorial Sloan Kettering Cancer Center
MedImmune LLC

Completed

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Withdrawn

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Oropharynx Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA)

Completed

Using Imaging to Assess Effects of THC on Brain Activity (fNIRS)

Intoxication Alcohol | Intoxication THC | Intoxication Combined Alcohol THC

United States
ModernaTX, Inc.

Terminated

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Ovarian Cancer | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Metastatic Colorectal Cancer

United States
Canadian Cancer Trials Group
University Health Network, Toronto; AstraZeneca

Active, not recruiting

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Breast Cancer

Canada
Samsung Medical Center

Active, not recruiting

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Gastric Adenocarcinoma | Malignant Melanoma

Korea, Republic of
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Metastatic Anaplastic Thyroid Cancer

United States
Fundación GECP

Completed

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. (S-REAL)

Small Cell Lung Cancer (SCLC)

Spain
Yonsei University

Active, not recruiting

A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

Sarcoma

Korea, Republic of
Universitaire Ziekenhuizen KU Leuven
AstraZeneca; European Organisation for Research and Treatment of Cancer - EORTC and other collaborators

Active, not recruiting

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO)

Oral Cavity Squamous Cell Carcinoma

Belgium
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Breast Cancer | Hormone Receptor Positive Tumor

United States
European Organisation for Research and Treatment...

Completed

Synergism of Immunomodulation and Tumor Ablation (ILOC)

Colorectal Cancer | Liver Metastases

France, Netherlands, Switzerland, Germany, Austria, Sweden
Northwestern University
National Cancer Institute (NCI); MedImmune LLC; Avon Breast Cancer Foundation

Completed

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Human Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditions

United States

Search clinical trials for: Durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations